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Abstract
Introduction: CT10 regulator of kinase (Crk) adaptor proteins (CrkI, CrkII and CrkL) play a role in integrating signals
for migration and invasion of highly malignant breast cancer cell lines. This has important implications, as elevated
CrkI/II protein levels were observed in a small cohort of breast cancer patients, which identified a potential role for
Crk proteins in breast cancer progression. Numerous in vitro studies identified a role for Crk proteins in cell motility,
but little is known about how Crk proteins contribute to breast cancer progression in vivo.
Methods: The clinical significance of Crk proteins in human breast cancer was assessed by analyzing published breast
cancer datasets using a gene expression signature that was generated following CrkII over-expression and by
examining Crk protein expression in tissue microarrays of breast tumors (n = 254). Stable knockdown of Crk (CrkI/CrkII/
CrkL) proteins was accomplished using a short hairpin RNA (shRNA)-mediated approach in two basal breast cancer cell
lines, MDA-231 1833TR and SUM1315, where the former have a high affinity to form bone metastases. Both in vitro
assays (cell migration, invasion, soft agar growth) and in vivo experiments (intra-cardiac, tibial and mammary fat pad
injections) were performed to assess the functional significance of Crk proteins in breast cancer.
Results: A gene signature derived following CrkII over-expression correlated significantly with basal breast cancers and
with high grade and poor outcome in general. Moreover, elevated Crk immunostaining on tissue microarrays revealed
a significant association with highly proliferative tumors within the basal subtype. RNAi-mediated knockdown of all
three Crk proteins in metastatic basal breast cancer cells established a continued requirement for Crk in cell migration
and invasion in vitro and metastatic growth in vivo. Furthermore, Crk ablation suppressed anchorage independent
growth and in vivo orthotopic tumor growth. This was associated with diminished cell proliferation and was rescued by
expression of non-shRNA targeted CrkI/II. Perturbations in tumor progression correlated with altered integrin signaling,
including decreased cell spreading, diminished p130Cas phosphorylation, and Cdc42 activation.
Conclusions: These data highlight the physiological importance of Crk proteins in regulating growth of aggressive
basal breast cancer cells and identify Crk-dependent signaling networks as promising therapeutic targets.
Introduction
Crk, or CT10 regulator of kinase, was originally isolated as
the oncogene fusion product of the CT10 chicken retro-
virus (v-Crk) [1]. Cellular homologues of v-Crk include
the c-Crk gene, which encodes two alternatively spliced
mRNAs that give rise to two proteins (c-CrkI and c-CrkII)
and a second gene, c-CrkL [2]. Crk adaptor proteins con-
tain Src homology 2 (SH2) and Src homology 3 (SH3)
domains, which mediate the formation of protein-protein
complexes. As adaptor proteins, Crk proteins are consid-
ered highly pleiotropic, as they have been proposed to reg-
ulate cell migration, invasion, and survival downstream of
integrins and various receptor tyrosine kinases [3]. For
instance, in response to hepatocyte growth factor, Crk
adaptor proteins are required for the dispersal of orga-
nized epithelial colonies, formation of lamellipodia and the
breakdown of adherens junctions, events that are critical
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to tumor cell dispersal and, hence, cancer progression [4].
Furthermore, over-expression of Crk promotes an invasive
phenotype regardless of upstream signaling, which identi-
fies Crk as a potential key regulator of cell invasion [5]. In
support of this, transient knockdown of CrkI/II resulted in
significant inhibition of migration and invasion of multiple
malignant breast (MDA-231, MDA-435s) and other
human cancer cell lines (HeLa, H1299, KB) [6], confirming
that CrkI/II are critical integrators of upstream signals for
cell migration and invasion and highlighting a potential
role for these adaptor proteins in metastatic spread.
Elevated expression of Crk proteins has also been
linked to cell transformation, with CrkI exhibiting the
highest transforming potential. CrkI, CrkII and CrkL
over-expressing fibroblasts proliferate in soft agar,
although only CrkI over-expressing fibroblasts form
tumors in nude mice [2,7,8]. However, a mouse model
over-expressing CrkL exhibited an increased incidence of
hematopoietic and epithelial cancers and a mammary
mouse model over-expressing CrkII was associated with
altered mammary gland development and accelerated
tumor development [9,10]. Although tumor incidence
was low in the latter study, the ability of CrkII to induce
a branching phenotype during a normally quiescent state
suggests that CrkII may play an active role in mammary
epithelial proliferation and remodeling [9]. This preco-
cious development, coupled with the fact that CrkII is
downstream of several signaling proteins involved in
breast cancer development, highlights the potential con-
sequence of elevated Crk proteins in the human disease.
Elevated levels of CrkI and CrkII mRNA and protein are
found in various human tumors, including glioblastoma
[11], gastric and breast cancers [6,12,13]. CrkI/II mRNA
expression was increased predominantly in advanced lung
tumors and those associated with poor survival, implying
that Crk proteins may play a key role in epithelial human
cancers [14].
The complexity and multi-step nature of tumor initia-
tion, maintenance and metastasis has hindered the eluci-
dation of key molecular processes defining breast cancer
progression. Although Crk proteins have been character-
ized in the context of cellular signaling, particularly
through over-expression studies, and demonstrate aber-
rant expression in multiple cancer types, including breast,
few studies have addressed the precise role of Crk proteins
in breast cancer-related processes in vivo. Since Crk is
proposed to be involved in many aspects of tumorigenesis,
dissecting whether Crk is required in tumor initiation and
progression is an important step towards developing tar-
geted therapeutics for breast cancer. Here, we demonstrate
that elevated Crk is significantly associated with highly
proliferative breast tumors of triple negative subtype and a
gene expression signature derived following CrkII over-
expression correlated with basal breast cancer, implicating
Crk signaling in an aggressive breast cancer phenotype. To
confirm the functional significance of Crk proteins within
basal breast cancer, we demonstrate that Crk proteins are
critical for the growth of breast cancer cells in vivo at both
orthotopic and metastatic sites, highlighting the physiolo-
gical importance of Crk proteins in regulating cancer sig-
naling. This data implicates Crk proteins not only in the
enhanced malignancy of breast cancer, but also in an
aggressive breast cancer phenotype.
Methods
Reagents, cell lines and retroviral transduction
The MDA-231 1833TR cell line was generously provided
by Joan Massagué in 2004. This cell line and its triple
reporter (TR) were previously described [15,16] and cells
used in this study were expanded from freeze downs
from 2004. The SUM1315 cell line was purchased from
Asterand (Detroit, MI, USA) in 2009 and cultured as in
[17] from freeze downs from 2009. Both cell lines under-
went standard mouse antibody production (MAP) testing
for pathogens, as well as mycoplasm testing. CrkL short
hairpin RNA (shRNA) (V2HS_43900, Open Biosystems,
Huntsville, AL, USA) was subcloned into LMP according
to [18]. pSuperCrkI/II constructs were made according
to the manufacturer’s protocol. The CrkI/II shRNA
sequence was based on the duplex published in [6]. Ret-
rovirally-generated LMP or LMP-CrkL shRNA cell lines
were subsequently infected with pSuper or pSuperCrkI/
II. CrkI/II rescue cell lines were made using pLXSP-CrkI
and pLXSH-CrkII constructs containing silent mutations
in the shRNA-targeted region from site directed muta-
genesis using the QuickChange Multi Site-Directed
Mutagenesis Kit from Stratagene (La Jolla, CA, USA).
Antibodies included: CrkI/II, Rac1 and p130Cas (BD
Transduction Laboratories, Mississauga, ON, Canada),
CrkII (Novus Biologicals, Oakville, ON, Canada), CrkL,
Cdc42 and actin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), phospho-p130Cas (Cell Signaling Technology,
Mississauga, ON, Canada), paxillin and alpha-tubulin
(Sigma-Aldrich, Oakville, ON, Canada), and AlexaFluor
488 phalloidin (Molecular Probes, Eugene, OR, USA).
Cellular assays
Cell spreading, migration and invasion assays are
described in [6]. Analysis was performed with ImageScope
(Aperio, Vista, CA, USA). A minimum of 300 cells were
counted per condition for cell spreading. For soft agar
assays, cells were plated as in [19], except grown in 5%
serum and quantified using Infinity Analyze Software
(Lumenera Corp., Ottawa, ON, Canada). Immunohisto-
chemistry and immunofluorescence were performed
according to [6,9]. Human breast tumor sections for
immunofluorescence were obtained courtesy of the Breast
Cancer Functional Genomics Group at McGill University.
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In vivo experiments
Female nude mice (six to eight weeks old, Charles Rivers)
were injected with 106 cells into the mammary fat pad;
tumor volumes were monitored bi-weekly and calculated
as described [20]. Cardiac injections were performed using
105 cells as described [15]. Mice were sacrificed six to
eight weeks post-injection. Tibial injections were per-
formed using 104 cells injected directly into the marrow
space. Ten mice were used per cell line and were sacrificed
four weeks post-injection. Tumor outgrowth within bone
was monitored according to [15]. Osteolytic lesions were
blindly scored using X-ray radiographs. Total tumor area
versus total tumor/bone interface was scored using
ImageJ. All animal experiments were carried out in accor-
dance with the guidelines of the McGill University Animal
Ethics Committee and the Canadian Council on Animal
Care as a protocol approved by the Facility Animal Care
Committee (Protocols #4170 and #5562). The human
tumor samples used in this study were collected from
breast cancer patients at time of surgery. Tissue collection
was conducted under protocols approved by the McGill
University Health Centre (MUHC) Research Ethics Board
(Protocols SUR-99-780 and SUR-00-966). All subjects pro-
vided written, informed consent.
Western blot analysis
Cells were serum starved for four hours, plated on col-
lagen for 30 minutes and protein lysates were resolved by
SDS-PAGE [6]. Detection of GTP-bound endogenous
Rac1 or Cdc42 was performed according to [21]. Densito-
metry was performed using ImageJ or Odyssey (LI-COR,
Guelph, ON Canada).
Crk signature and microarray profiling
A Crk signature was derived from expression analysis of
T47D-CrkII cell lines [9] by selecting genes significantly
differentially expressed between T47D and T47D-CrkII
cell lines (FDR corrected P-value < 0.05 and fold change >
2, GSE ID: GSE30731). Expression of this signature was
examined in breast cancer datasets and a breast cancer
cell line dataset [22-27]. Molecular subtypes were deter-
mined using PAM50 centroids [23]. Patients were ordered
based on correlation with the expression of the CRK sig-
nature in tumor samples. The association between patient
ordering, molecular subtype and grade was determined
using a Krusal-Wallis rank sum test. Analysis was con-
ducted using Bioconductor [28].
Tissue microarrays
Tissue microarray 1 (TMA-1) consisted of 113 patients
diagnosed with breast cancer at the Centre Hospitalier de
l’Universite de Montreal, Hôtel Dieu, and Notre Dame
and consisted of low grade (Grade I, n = 15) and high
grade (Grade III, n = 74) ductal carcinomas and typical
(n = 9) and atypical (n = 15) medullary carcinomas [29],
approved by the research ethics committee (Centre Hos-
pitalier de l’Université de Montréal). TMA-2 consisted of
141 cases selected from consenting patients who had
undergone surgical resection for breast cancer at the
Centre Hospitalier de l’Université de Montréal, Hôtel
Dieu. Representative tumor areas were annotated by a
pathologist, and two single core TMAs were constructed
in parallel. The TMA-2 clinical parameters included sam-
ples from grade 1 (n = 17), grade 2 (n = 39), and grade 3
(n = 83) patients. Tumors were of ductal (n = 102), lobu-
lar (n = 20) or other (n = 19) morphology. Immunohisto-
chemistry for HER2, ER and PR identified 29 triple
negative breast tumors. Crk positivity and the percentage
of Ki67 positive cells were assessed using ImageScope.
Crk staining intensity was also reported by a pathologist
and an independent observer.
Statistical analysis
A two-sample variance student’s t-test was used to assess
for statistical significance. Kendall’s tau non-parametric
statistical analysis was used to assess significance between
Crk expression and Ki67 within TMA-1 and TMA-2.
Results
A CrkII-associated transcriptional signature and Crk
protein expression correlate with a proliferative basal
breast cancer subtype
Crk over-expression has been linked to various aspects of
tumorigenesis, including cell migration, invasion and
anchorage independent growth [2,7,30]. Although elevated
CrkI/II proteins have been reported in a small cohort (n =
20) of breast cancer samples [6], no studies have addressed
if elevated Crk, or its signaling pathways, are associated
with known clinical variables or breast cancer subtype.
Gene expression profiling is a valuable tool to search for
links between signaling networks and defined steps of
tumor progression. Thus, to investigate an association
between Crk-mediated signaling with breast cancer out-
come, we constructed a gene expression signature com-
posed of 151 genes that are most differentially expressed
following CrkII over-expression (Additional file 1) [9].
This CrkII transcriptional signature was derived following
gene expression profiling of the breast cancer cell line
T47D versus T47D cells over-expressing CrkII [9]. Expres-
sion of ‘Crk signature’ genes was examined in five inde-
pendent datasets (Figure 1a, Additional file 2) for a total of
1,469 breast cancer patients [22-26]. In each dataset,
patients were ordered by expression of Crk signature
genes (Additional file 1). Notably, the ‘Crk gene signature’
strongly correlated with the basal molecular subtype (P <
6.7e-14) in the NKI dataset (Figure 1a) [31]. In addition,
there was a significant correlation with the basal subtype
within the four additional breast cancer datasets examined
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(Ivshina, Loi, Parker and Wang, Additional file 2). The Crk
signature also significantly associated with high tumor
grade (P < 6.4e-12) and poor outcome (P = 0.00472)
within the NKI (Figure 1a) and the additional four breast
cancer datasets examined (Additional file 2). Thus, a
CrkII-dependent gene signature is associated with high
grade, basal breast cancers and poor outcome. The T47D
cancer cell line used to generate the Crk gene signature is
identified as a luminal subtype [27], thus, a dataset derived
from a panel of breast cancer cell lines [27] was examined
to confirm that the Crk signature is indeed more common
within the basal subtype. Similar to the data obtained
using datasets derived from human breast cancer patients,
the Crk signature more closely correlated with the two
basal subtypes (Basal A and Basal B) typically found within
a subset of breast cancer cell lines (Additional file 3). Since
an expression signature associated with high grade basal
tumors and cell lines could be generated from the luminal
Figure 1 Crk pathway signature in breast cancer is associated with basal subtype and tumor grade. Heatmap of Crk signature in NKI
breast cancer dataset. Bars on the left indicate if genes increased or decreased expression in the T47D-CrkII cell line compared to control. The
patients are ordered by correlation of the expression of these 151 genes in the patients sample to the Crk signature. Patients were separated
into two subgroups: high correlation (correlation > 0.17, red) and low correlation (correlation < 0.17, blue). On heatmap, blue indicates increased
expression; yellow indicates decreased expression. The Crk signature was used to examine overall 20 year outcome; the red line indicates
patients who exhibit the Crk gene signature, whereas the blue line represents patients whose tumors do not express the signature (A). TMA-1
was stained with Ki67, CrkI/II, CrkII or CrkL specific antibodies in high (Grade 3) and low (Grade 1) grade tumors. Images taken using ImageScope;
scale bar represents 50 μm. TMA-1 was utilized to examine CrkI/II and Ki67 expression in relation to tumor grade. Errors bars represent standard
error of the mean (SEM) (B). Statistically significant data is illustrated as (* = P < 0.05, ** = P < 0.01, *** = P < 0.001).
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T47D cell line over-expressing CrkII, it provides evidence
for a role for Crk in promoting key signaling events in the
progression of basal breast cancer.
To confirm whether elevated Crk proteins are associated
with a breast cancer subtype or outcome, we also per-
formed immunohistochemical staining using various Crk
antibodies (CrkI/II, CrkII, CrkL C-20, CrkL H-62) on
two independent human breast cancer tissue TMAs
(Figure 1b, Additional file 4). TMA-1 consisted of 113
patients while the second, TMA-2, consisted of 141 pri-
mary breast cancer tissue cores. TMA-1 consisted of both
low grade (Grade 1, n = 15) and high grade (Grade 3, n =
74) ductal carcinomas [29]. Within this dataset, CrkI/II
protein was significantly elevated in Grade 3 tumors versus
Grade 1 tumors (Figure 1b). As expected, Ki67 antigen, a
measure of proliferative index, also correlated strongly
with Grade 3 tumors (Figure 1b). Importantly, within the
high grade basal tumors in both TMA datasets, CrkI/II
and CrkL protein levels correlated with proliferation, as
assessed using Kendall’s tau non-parametric statistical ana-
lysis (Table 1), demonstrating a strong link between ele-
vated Crk protein and an aggressive tumor phenotype.
Together, these observations identify a significant correla-
tion of elevated Crk protein with high grade and poor out-
come subtypes in human breast cancer.
Crk proteins are required for cancer cell cytoskeletal
organization, migration and invasion
As elevated Crk proteins and a Crk gene signature are
associated with an aggressive and proliferative basal
breast cancer phenotype as well as basal breast cancer
cell lines, we sought to examine the functional signifi-
cance of Crk proteins in integrating signals for breast
cancer progression. Thus, shRNAs were utilized to
knock down all three Crk proteins in MDA-231 1833TR
cells, a metastatic subpopulation of the basal MDA-231
cell line, that has a high affinity to form bone metastases
[15]. Using CrkI/II and CrkL shRNA in pSuper and
LMP vectors, respectively, multiple independent 1833TR
cell lines were established with stable knockdown of Crk
proteins (Figure 2a).
To first assess whether loss of Crk proteins affected
proliferation, an Alamar Blue assay was performed. No
significant differences in cell proliferation were observed
(Figure 2b). In contrast, there was a significant decrease
in cell migration and invasion towards 10% fetal bovine
serum (FBS) in stable Crk knockdown cells compared to
control cells (Figure 2c, d). Transient knockdown of
CrkI/II and CrkL in combination resulted in a greater
decrease in migration and invasion than single knock-
down (CrkI/II or CrkL) alone (Additional file 5), support-
ing that Crk proteins have an additive role in promoting
cell migration and invasion, and demonstrating a require-
ment to knock down all three Crk proteins within the
1833TR aggressive breast cancer cell line.
Since Crk proteins are implicated in integrating signals
downstream of integrins, the importance of Crk for integ-
rin engagement was assessed by plating cells on fibronec-
tin. When cells were grown on fibronectin, staining of
paxillin, a marker of focal adhesions, demonstrated that
paxillin-positive adhesions were present within control
and Crk knockdown cells (Figure 2e). However, whereas
lamellipodia were identified in control cells, Crk knock-
down cells failed to develop polarized membrane ruffles or
lamellipodia and instead, dense cortical actin was observed
(Figure 2e). In addition, delayed cellular spreading was
found in Crk knockdown cells 0.5 and one hour post-
plating (Figure 2f), establishing that diminished Crk
expression decreased integrin-mediated spreading.
As Crk has been shown to regulate Rho GTPases
involved in cell spreading and migration, we examined the
activity of Rac1, which is known to regulate lamellipodia
formation and cell migration [32]. Using a pull-down
assay, small decreases in endogenous Rac GTP levels were
consistently observed in Crk knockdown cells upon plat-
ing on collagen or upon stimulation with serum (Addi-
tional file 6). In contrast, a substantial decrease in Cdc42
activation was observed following serum stimulation
(Additional file 6). Thus, knockdown of Crk proteins does
not significantly disrupt Rac-dependent signals, but is
required for activation of Cdc42 upon serum stimulation.
In conclusion, alterations in cell morphology, diminished
cellular spreading, and significant decreases in cell migra-
tion and invasion in vitro are caused by loss of Crk
Table 1 Crk protein expression correlates with Ki67
within the basal subtype
Antibody Correlation to Ki67 proliferation index
(% cells Ki67 positive)
CrkI/II (TMA-1) Correlation Coefficient 0.289
P-value (2 tailed) 0.019
number 43
CrkI/II (TMA-2) Correlation Coefficient 0.323
P-value (2 tailed) 0.016
number 28
CrkII (TMA-2) Correlation Coefficient 0.483
P-value (2 tailed) 0.00024
number 29
CrkL (C-20) (TMA-2) Correlation Coefficient 0.483
P-value (2 tailed) 0.00024
number 29
CrkL (H-62) (TMA-2) Correlation Coefficient 0.547
P-value (2 tailed) 0.00003
number 29
CrkI/II expression was examined in relation to Ki67 expression within 43 basal
tumors using TMA-1. TMA-2 was utilized to examine Crk protein expression
(using four different Crk antibodies recognizing CrkI/II, CrkII or CrkL) relative to
Ki67 within 29 basal tumors. Kendall’s tau non-parametric statistical analysis
was used to assess for significance. TMA, tissue microarray.
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Figure 2 Knockdown of Crk alters migration and invasion, cell morphology and adhesion. Western blot of Crk proteins from whole cell
lysates with actin as loading control (A). Alamar blue assay (n = 3) of control and Crk shRNA cells (B). Control and Crk shRNA cells were analyzed
for migration (C) and invasion (D) using transwells (n = 3). Control and Crk shRNA cells plated on fibronectin coated coverslips (63x). Control cells
exhibit lamellipodia (white arrowheads) compared to Crk shRNA cells, which lack these structures (white arrowheads). Cells co-stained with anti-
paxillin and phalloidin. Scale bars represent 10 μm (E). Cell spreading (n = 3) was quantified by counting the total number of spread cells versus
total cell number (F). Error bars represent SEM. Statistically significant data illustrated as (* = P < 0.05, ** = P < 0.01, *** = P < 0.001).
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proteins and are associated with perturbations in Cdc42
activation.
Crk proteins are required for breast cancer growth in the
bone microenvironment
Loss of Crk proteins impaired the ability of metastatic
breast cancer cells to migrate, invade and adhere in vitro,
thus, we examined how loss of Crk would affect bone
metastasis in vivo following intra-cardiac injection, which
takes into account several aspects of the metastatic cas-
cade, including survival in the bloodstream, extravasation
and secondary outgrowth. As stated previously, the
MDA-231 1833TR cell line is a highly metastatic subpo-
pulation when compared to the parental MDA-231 cell
line and has a high affinity to form bone metastases [15].
Following intra-cardiac injection, cells are dispersed
body-wide, and based on the observations that loss of
Crk affects cell migration and invasion, we hypothesized
that Crk proteins may modulate the ability of cells to
extravasate and initiate early colonization steps. The
1833TR cells express luciferase, allowing for imaging of
metastatic capacity [16]. Ablation of Crk significantly
diminished the growth of metastatic bone lesions as
assessed by bioluminescence, which correlated with
decreases in the overall number and size of osteolytic
lesions, as determined by X-ray analysis (Figure 3a-c).
Interestingly, several of the animals injected with Crk
knockdown cells failed to develop any metastatic lesions,
relative to control cells in which 100% of the animals
developed metastatic bone lesions (Table 2).
Since intra-cardiac injection encompasses multiple steps
of the metastatic cascade, we wanted to establish whether
Crk knockdown affects tumor outgrowth in the bone
microenvironment. The tibial injection model [33] was
chosen to focus our investigation on the importance of
Crk proteins in mediating tumor cell interactions with the
microenvironment, thereby excluding any possible effects
that loss of Crk may have on tumor cell survival in circula-
tion, endothelial adhesion, and extravasation. When com-
pared to control cells, loss of Crk decreased tumor
Figure 3 Crk proteins are required for efficient breast cancer outgrowth in bone. Outgrowth of 1833TR control (n = 7 for control 1, n = 4
for control 2) or Crk shRNA cells (n = 6 for Crk shRNA1, n = 6 for Crk shRNA 2) was measured by bioluminescence. Representative luciferase
images at Day 40 are shown, closely resembling the mean bioluminescence values (A). Bioluminescence of positive limbs was quantified as
relative luciferase units (RLU) over time. Averages from each cell line were plotted on a log scale +/- SEM (B). Representative X-ray images from
negative control, control 1833TR and Crk shRNA mice. The average number and size of osteolytic lesions was blindly scored. Both control (n = 8)
and Crk knockdown cohorts (n = 6) that exhibited osteolytic lesions were pooled for analysis (C). Statistically significant data illustrated as (* = P
< 0.05, ** = P < 0.01, *** = P < 0.001).
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outgrowth in the tibia, as measured by bioluminescence
imaging (Additional file 7), which was associated with a
moderate decrease in the overall number and size of
osteolytic lesions (Additional file 7). Thus, Crk proteins
are required for outgrowth of 1833TR breast cancer cells
in the bone microenvironment. Since differences observed
between control and Crk knockdown 1833TR cells were
more dramatic in the intra-cardiac model, loss of Crk may
also contribute to bone metastasis.
Crk proteins are required for mammary tumor growth
Since a significant delay in the outgrowth of 1833TR cells
was observed in the bone microenvironment, we investi-
gated whether loss of Crk would affect outgrowth in the
primary site, the mammary fat pad. Similar to the intra-
cardiac injection, seven out of the 16 animals injected with
Crk knockdown cells failed to develop mammary tumors
that reached a detectable size and the tumors that did
derive were significantly delayed, taking twice as long as
control cells to reach 500 mm3 (Figure 4a, Table 2).
Importantly, endpoint mammary tumors derived from
control and Crk shRNA cells expressed similar levels of
Crk protein (Additional file 8), indicating that Crk knock-
down cells fail to form tumors and selective pressures
exist within tumors to lose expression of Crk-targeting
shRNAs, allowing re-expression of Crk proteins for tumor
progression.
To investigate how mammary tumor outgrowth is
altered by Crk knockdown, 1833TR cells were analyzed
three days post-injection for proliferation and apoptosis.
Relative to control cells, Crk knockdown significantly
decreased proliferation, as assessed through Ki67 staining
(Figure 4b) but not apoptosis (Additional file 8). Impor-
tantly, re-expression of non-shRNA targeted CrkI/II res-
cued in vivo proliferation, indicating a specific requirement
of CrkI/II for sustained tumor growth (Figure 4b, Addi-
tional file 8). Analysis of microscopic lesions eight days
post-injection revealed smaller lesions derived from Crk
knockdown cells relative to control and CrkI/II rescue
cells, highlighting the importance of Crk for initiation and
maintenance of 1833TR induced tumors (Figure 4c). These
data were unexpected considering Crk knockdown cells
grow at similar rates to control cells in vitro (Figure 2b).
Hence, we examined whether diminished Crk expression
affects anchorage-independent growth. Loss of Crk signifi-
cantly impaired the ability of 1833TR cells to grow in soft
agar compared to control cells and re-expression of CrkI/II
proteins rescued this phenotype (Figure 4d), consistent
with a specific requirement for Crk in anchorage-indepen-
dent growth.
To address whether the phenotypes observed upon Crk
knockdown are specific to 1833TR cells, Crk knockdown
was established in another basal breast cancer cell line,
SUM1315. In a similar manner to 1833TR, Crk knock-
down significantly attenuated anchorage-independent
growth and perturbed in vivo proliferation of SUM1315
cells when injected into the mammary fat pad, confirming
that Crk is required for tumor progression in other basal
breast tumor cell lines (Figure 4e, f, Additional file 8). Loss
of Crk also significantly impaired the ability of SUM1315
cells to migrate and invade (Additional file 8), meaning
that Crk knockdown severely impairs the growth, migra-
tion, invasion, and proliferation of several basal breast
tumor cells.
Loss of Crk leads to decreased p130Cas phosphorylation
As previously mentioned, Crk adaptor proteins are known
downstream integrators of integrin-mediated signaling and
several studies have linked integrin signaling to tumor pro-
gression [34-36]. To understand the biochemical conse-
quences of the diminished cell spreading and migration
following Crk ablation, as well as the perturbations in
tumor outgrowth, we examined known Crk-dependent
signaling pathways associated with integrin activation.
Integrin signaling induces phosphorylation of p130Cas
(Crk-associated substrate), a scaffolding protein implicated
in actin cytoskeleton reorganization, cell migration and
spreading [37]. p130Cas was originally identified as a Crk
SH2 domain-binding protein whose tyrosine phosphoryla-
tion is elevated upon v-Crk transformation of fibroblasts
[37]. Immunofluorescence staining and confocal imaging
of cells, one hour post-plating on fibronectin, revealed
reduced phospho-p130Cas staining in Crk knockdown
1833TR cells relative to control cells. Interestingly, phos-
pho-p130Cas was found predominantly in the cytoplasm
rather than at membrane protrusions, as illustrated in con-
trol cells (Figure 5a). By Western blot analysis and quanti-
fication using digital software (Odyssey), phosphorylation
of p130Cas was significantly reduced in Crk knockdown
cells that demonstrated delayed cell spreading (Figure 5b).
Thus, the delayed cell spreading correlated with decreased
levels of phosphorylated p130Cas upon Crk knockdown
Table 2 Comparison of ‘take rates’ between the control 1833TR cells and the Crk shRNA cells from the various in vivo
experiments
In vivo assay Control 1 Control 2 Crk shRNA1 Crk shRNA 2 Controls (Total) Crk shRNA (Total)
Cardiac 7/7 4/4 5/6 3/6 11/11 (100%) 8/12 (66.7%)
Tibial 8/16 7/16 10/16 4/16 15/32 (46.9%) 14/32 (43.8%)
Mammary Fat Pad 9/10 8/10 6/8 3/8 17/20 (85%) 9/16 (56.3%)
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Figure 4 Crk proteins are essential for outgrowth in the primary site. Mammary tumor outgrowth was measured and the average volume
of control (n = 10 per cell line) and Crk shRNA tumors (n = 8 per cell line) plotted over time +/- SEM (A). H & E (5x) and Ki67 (20x) staining
were performed on sections from control, Crk shRNA and CrkI/II rescue samples three days post-injection. Scale bars 50 μm. Average cell
proliferation +/- SEM was quantified using ImageScope (B). Representative H&E staining (2x) of lesion size eight days post-injection are shown.
Scale bars 10 μm. Average lesion size eight days post-injection was plotted +/- SEM (C). Soft agar growth of control, Crk shRNA and CrkI/II
rescue 1833TR cell lines; mean +/- SEM. Scale bars 100 μm (D). Soft agar growth of control and Crk shRNA SUM1315 cell lines; mean +/- SEM.
Scale bars 100 μm. Soft agar quantified using Infinity Analyze (E). Ki67 (20x) staining of sections from control and Crk shRNA SUM1315 tumor
samples three days post-injection. Scale bars 50 μm. Average cell proliferation +/- SEM quantified using ImageScope (F). Statistically significant
data illustrated as (* = P < 0.05, ** = P < 0.01, *** = P < 0.001).
Fathers et al. Breast Cancer Research 2012, 14:R74
http://breast-cancer-research.com/content/14/3/R74






































Control 1 Control 2 Crk shRNA 1 Crk shRNA 2
A
B















































Figure 5 Crk knockdown alters p130Cas phosphorylation. Control and Crk shRNA MDA-231 1833TR cells plated on fibronectin one hour
before fixation; stained for phospho-p130Cas and phalloidin. Phospho-p130Cas is prominent at membrane ruffles in control cells (white
arrowheads), but cytosolic in Crk shRNA cells, with decreased accumulation of phalloidin at cell periphery (white arrowheads). Scale bars 10 μm
(A). Western blot of proteins from control and Crk shRNA MDA-231 1833TR cells plated for 0.5 hour on fibronectin were quantified using
Odyssey software. Phospho-p130Cas levels were normalized to total p130Cas levels (n = 3) (B). Immunofluorescence of CrkI/II and
phosphorylated p130Cas was performed on sections from control and Crk shRNA MDA-231 1833TR samples three days post-injection. Scale bars
20 μm (C).
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and a diminished ability of phospho-p130Cas to engage in
adhesions, supporting that Crk ablation impairs integrin
signaling at least in part through reduced p130Cas phos-
phorylation and localization.
In order to assess whether impaired integrin signaling
correlated with the decreases observed in tumor out-
growth, 1833TR and SUM1315 tumor lesions derived
three days post-injection were immunostained for phos-
pho-p130Cas and CrkI/II protein expression. Diminished
levels of phospho-p130Cas were detected within Crk
knockdown lesions relative to control lesions, supporting
a perturbation in downstream integrin signaling in vivo
as well as in vitro (Figure 5c, Additional file 9). A similar
correlation was also observed in human breast cancer
tumors. Breast tumors expressing low levels of CrkI/II, as
visualized by confocal microscopy, exhibited diminished
phosphorylation of p130Cas (Additional file 10). Conver-
sely, breast tumors expressing high levels of CrkI/II
demonstrated robust tyrosine phosphorylation of
p130Cas (Additional file 10). Hence, in human breast
cancers, high Crk protein expression is associated with
tyrosine phosphorylation of p130Cas and supports our in
vitro data illustrating that loss of Crk is associated with
reduced p130Cas phosphorylation.
Discussion
Although elevated Crk proteins are documented in sev-
eral human cancers, Crk expression and signaling had
not been well characterized in human breast cancer.
Thus, it is of particular significance that a gene signature
derived following CrkII over-expression correlates with
the basal subtype in both human patients and breast
cancer cell lines, and is associated with poor prognosis
and decreased survival [31]. Using immunohistochemis-
try, we observed elevated CrkI/II and CrkL proteins in
both high-grade tumors and proliferative breast cancers
of the triple negative subtype, consistent with elevated
Crk proteins being associated with aggressive breast can-
cer. The transcriptional Crk signature was also associated
with high tumor grade and poor 20-year survival in mul-
tiple gene expression datasets from breast cancers. In
support of this, CrkI/II are over-expressed in poorly dif-
ferentiated and highly proliferative lung tumors [14],
implicating Crk proteins in the progression from early to
advanced states of disease.
The molecular mechanisms governing the induction and
progression of basal breast cancer are poorly understood,
and targeted therapies are lacking. Notably, the aggressive
MDA-231 1833TR and SUM1315 cells used in this study
are derived from the Basal B breast cancer subtype, which
is associated with the Crk gene signature [27]. Using these
basal breast cancer cell lines as a model, we demonstrate
that Crk proteins are critical for growth in the mammary
fat pad and bone. Interestingly, all mammary tumors that
form with long latency from Crk knockdown MDA-231
1833TR cells expressed Crk proteins at levels that were
similar to tumors derived from control cells, indicating
that strong selective pressures exist within tumors for re-
expression of Crk proteins for tumor progression.
Loss of Crk proteins abrogated the ability of aggressive
MDA-231 1833TR breast cancer cells to grow in the bone
after both intra-cardiac and tibial injections. Since loss of
Crk diminished outgrowth in the tibia as well as the mam-
mary fat pad, Crk proteins are likely required for tumor
outgrowth regardless of the microenvironment. This is
consistent with observations that loss of CrkI/II decreased
the ability of ovarian cancer cells to grow within the peri-
toneal cavity and that ectopic expression of the microRNA
miR-126, whose putative target is Crk, prevented out-
growth of gastric cancer cells in the lung and outgrowth of
breast cancer cells in the lung, bone and mammary fat pad
[13,38,39]. These data have important implications, as Crk
proteins are elevated in many cancer types, including
breast [6,11,12,14].
Since differences in bioluminescence observed between
Crk knockdown and control cells following tibial injec-
tion were not as dramatic as those observed after intra-
cardiac injection, the effect on metastasis formation may
not be solely attributed to the effect on tumor outgrowth.
The progression of cancer to metastasis is dependent, in
part, on the deregulation of signaling pathways involved
in cell migration and invasion. Downstream of integrins,
Crk proteins can mediate migration through their asso-
ciation with the scaffold protein, p130Cas and the Rac
exchange factor Dock180 [34]. Through these interac-
tions, a role for Crk has been proposed in the regulation
of cell migration, invasion, and phagocytosis, several of
which have been demonstrated in vivo in Caenorhabditis
elegans [3]. In the basal breast tumor cells examined
here, loss of Crk reduces cell migration and invasion.
However, although Crk has been well characterized
upstream of Rac [34], we do not observe a strong correla-
tion between Crk knockdown and overall Rac GTP levels,
as assessed through pulldown assays. This suggests that
Crk may be unlinked from Rac activation in the MDA-
231 1833TR cell line or that Crk may affect the subcellu-
lar localization of Rac1 rather than its activation [40].
MDA-231 cells express mutant Ras (KRas G13D) [41],
which is known to activate PI3K signaling, that can sub-
sequently activate the Rac guanine nucleotide exchange
factors, Sos and Vav1 [42] providing an alternative
mechanism to activate Rac. However, these are insuffi-
cient to promote cell migration and invasion following
Crk knockdown. A similar small reduction in Rac activa-
tion has been observed upon CrkI/II knockdown in
MCAS ovarian cancer cells [38], further supporting the
idea that Crk represents only one of several pathways
that can activate Rac1.
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Despite the small decreases in Rac activity, we
observed a significant decrease in Cdc42 GTP levels in
Crk knockdown cells upon serum stimulation. Cdc42 is
involved in filopodia formation, as well as cell polarity
and invadopodia [43] and has also been implicated in
regulating Ras-mediated cell transformation [44]. Thus,
our data support studies that identify Crk in signaling
upstream of Cdc42 [45] and demonstrates that 1833TR
breast tumor cells are dependent, at least in part, on
Crk for activation of this GTPase, providing a potential
mechanism for diminished in vivo tumor growth, as well
as cell migration and invasion that are required for
metastatic spread.
A role for integrin signaling in breast tumor progres-
sion is supported by studies demonstrating that b1 integ-
rin inhibitory antibody decreased the number and size of
mammary tumors and suppressed the growth of MDA-
231 cells cultured in 3D extracellular matrix through
decreased proliferation and enhanced apoptosis [35,36].
Additional studies examining metastases determined that
impairment of integrin signaling is required, not for
extravasation, but secondary outgrowth, highlighting the
importance of integrin dependent signals for proliferation
and survival in vivo [46,47]. Our studies identify a key
role for Crk in this process. Following Crk knockdown,
integrin-dependent cell spreading and tyrosine phosphor-
ylation of p130Cas, a downstream target following integ-
rin engagement, are impaired, and both MDA-231 and
SUM1315 cells with Crk knockdown have decreased abil-
ity to grow in soft agar and impaired tumor outgrowth
associated with diminished proliferation in vivo.
Crk proteins may be necessary to sustain the phos-
phorylation status of their SH2 domain-binding part-
ners. Cells transformed with v-crk show elevated levels
of tyrosine phosphorylation of Crk SH2 domain-binding
proteins, including p130Cas [1,48-51] and CrkI/II is
required for sustained phosphorylation of SH2 domain-
binding protein Gab1 in response to growth factor sti-
mulation [52]. In support of a requirement for Crk pro-
teins for p130Cas signaling, we observe decreased
tyrosine phosphorylation and mislocalization of p130Cas
from the plasma membrane in basal breast cancer cells
in vitro, as well as short term tumor assays in vivo fol-
lowing Crk knockdown. Decreased phosphorylation of
p130Cas was also observed in human breast cancer tis-
sue biopsies that displayed low levels of CrkI/II proteins,
whereas elevated levels of p130Cas tyrosine phosphory-
lation correlated with high levels of Crk supporting the
idea that Crk levels modulate signaling through p130Cas
in human breast cancer in vivo.
Conclusions
Elevated levels of Crk proteins (CrkI, CrkII, CrkL) are
observed in human cancers, including those of epithelial
origin, such as breast. Despite in vitro studies on cell
transformation, migration and invasion, the precise role
of Crk adaptor proteins in epithelial derived breast can-
cers and their correlation to human clinical parameters
in vivo is poorly understood. We demonstrate the clinical
significance of Crk proteins in human breast cancer
using TMAs (n = 254), revealing a significant association
between Crk protein expression with highly proliferative
tumors and basal breast cancers of poor outcome. More-
over, a gene expression signature derived following CrkII
over-expression significantly correlated with basal breast
cancer and poor outcome. As a model to study the func-
tional significance of Crk adaptor proteins within basal
breast cancer, we utilized two basal breast cancer cell
lines and demonstrated that Crk proteins are important
for cellular adhesion, migration, invasion and in vivo pro-
liferative breast tumor outgrowth. The data generated
from this study identify Crk proteins, or Crk-dependent
signaling pathways, such as p130Cas, as potential targets
for the basal subtype of breast cancer.
Additional material
Additional file 1: The Crk gene signature is composed of 151 genes
that are differentially expressed following CrkII over-expression in
T47D cells.
Additional file 2: Additional microarray datasets illustrating an
association of the Crk gene signature with basal molecular subtype
and high tumor grade. Heatmaps of the Crk signature in the Ivshina,
Loi, Parker and Wang breast cancer datasets. The Crk signature is derived
from CrkII over-expressing T47D cell lines. The bars on the left indicate if
the gene had increased or decreased expression in the CrkII cell line
compared to the control. The patients are ordered by correlation of the
expression of these 151 genes in the patients sample to the Crk
signature. Blue indicates increased expression whereas yellow indicates
decreased expression. The association between patient ordering,
molecular subtype and grade was determined using a Krusal-Wallis rank
sum test.
Additional file 3: There is an association with the Crk gene
signature and the basal molecular subtypes found within breast
cancer cell lines. Heatmap of the Crk signature in the Neve breast
cancer cell line dataset. The Crk signature is derived from CrkII over-
expressing T47D cell lines. The bars on the left indicate if the gene had
increased or decreased expression in the CrkII cell line compared to the
control T47D cell line. The breast cancer cell lines are ordered by
correlation of the expression of these 151 genes in the cell line to the
Crk signature. Blue indicates increased expression whereas yellow
indicates decreased expression. Within the gene cluster category, blue
represents luminal, pink represents Basal A and dark red represents Basal
B subtypes.
Additional file 4: CrkI/II positivity within human breast cancer tissue
microarrays. A representative image of CrkI/II immunohistochemical
staining within TMA#1. Image taken using ScanScope software.
Additional file 5: All 3 Crk proteins are required for sufficient
decreases in cell migration and invasion. MDA-231 1833TR cells were
transiently transfected and analyzed for their migration (A) and invasion
(B) capacity in the presence of either mock transfected, scramble siRNA,
CrkI/II, CrkL siRNA or both CrkI/II and CrkL siRNA in combination. Image
analysis of these assays was carried out using Scion Image software. A
minimum of three experiments were performed. Error bars represent the
standard error of the three experiments (A, B). Western blot analysis of
proteins from whole cell lysates (MDA-231 1833TR) with an anti-CrkI/II or
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anti-CrkL sera was performed and actin protein levels were used as a
loading control (C). All data that are statistically significant is illustrated as
follows (* represents P < 0.05), ** represents P < 0.01, *** represents P <
0.001).
Additional file 6: Crk knockdown alters Cdc42 activation but does
not significantly impact Rac activation. Rac1 pulldown experiments
were performed after a four hour serum starvation, followed by lysis 30
minutes post-plating on collagen. All samples were analyzed at the same
time, allowing for comparisons. The GTP bound form of endogenous Rac
was precipitated by GST-CRIB and probed for anti-Rac1 sera. Total
endogenous levels of Rac were visualized by immunoblot. Activated
levels of Rac1 were quantified and compared to total Rac1 levels (n = 6)
(A). In response to serum, Rac and Cdc42 activation was assessed
utilizing GST-Pak-PBD or GST-WASP as binding partners for GTP loaded
Rac and Cdc42 respectively. Pulldown experiments were performed after
a four hour serum starvation, followed by 15 minutes serum stimulation.
All samples were analyzed at the same time, allowing for comparisons.
The GTP bound form of endogenous Rac was precipitated by GST-Pak-
PBD and probed for anti-Rac1 sera. Total endogenous levels of Rac were
visualized by immunoblot. Activated levels of Rac1 were quantified and
compared to total Rac1 levels (n = 4) (B). The GTP bound form of
endogenous Cdc42 was precipitated by GST-WASP and probed for anti-
Cdc42 sera. Total levels of endogenous Cdc42 were visualized by
immunoblot. Activated levels of Cdc42 were quantified as described
above (C). Error bars represent SEM. All data that are statistically
significant is illustrated as follows (* represents P < 0.05), ** represents P
< 0.01, *** represents P < 0.001).
Additional file 7: Crk proteins are required for efficient outgrowth
of breast cancer cells in the tibia. MDA-231 1833TR control cells or
those expressing Crk shRNA were injected directly into the tibia and
tumor outgrowth was measured by bioluminescence imaging. Tumor
outgrowth within the tibia was quantified using limbs positive for
bioluminescent activity, measured as relative luciferase units (RLU) over
time and plotted on a log scale as the mean +/- SEM (A). The average
number and size of osteolytic lesions from pooled control (n = 9) and
Crk knockdown samples (n = 5) was quantified and plotted with SEM (B).
All data that is statistically significant is illustrated as follows (* represents
P < 0.05), ** represents P < 0.01, *** represents P < 0.001).
Additional file 8: Crk expression and growth kinetics in vitro and in
vivo. Western blot analysis of Crk protein expression levels from tumor
endpoint (A). Paraffin embedded sections of mammary tumors derived
from 1833TR control and Crk shRNA cells were stained for Ki67 (positive
staining represented by black arrows) and TUNEL (positive staining
represented by black arrows). No significant differences were observed
between control and Crk knockdown tumors for Ki67 and TUNEL. All
images taken at 20x where the scale bar represents 50 μm. Arrows
represent area of insert (B). CrkI/II rescue was examined via Western blot
analysis of whole cell lysates (MDA-231 1833TR) with an anti-CrkI/II or
anti-CrkL sera. Actin protein levels were used as a loading control (C).
Paraffin embedded sections of mammary tumors derived from 1833TR
control, Crk shRNA and CrkI/II rescue cells were stained for apoptosis via
TUNEL staining and quantified using ImageScope (D). Crk knockdown of
SUM1315 cells was examined via Western blot analysis of whole cell
lysates with an anti-CrkI/II or anti-CrkL sera. Alpha-tubulin protein levels
were used as a loading control (E). Control and Crk shRNA SUM1315 cells
(8 × 104 cells) were plated on transwells and were analyzed for
migration (F) and invasion (G) towards 10% FBS 24 hours post-plating
then quantified using ImageScope software (n = 3). All data that is
statistically significant is illustrated as follows (* represents P < 0.05), **
represents P < 0.01, *** represents P < 0.001).
Additional file 9: Phosphorylated p130Cas is diminished in lesions
derived from Crk knockdown cell lines. Immunofluorescence of CrkI/II
and phosphorylated p130Cas was performed on paraffin embedded
sections from control and Crk shRNA MDA-231 1833TR samples three
days post-injection. Scale bars 20 μm (A). Immunofluorescence of CrkI/II
and phosphorylated p130Cas was performed on paraffin embedded
sections from control and Crk shRNA SUM1315 samples 3 days post-
injection. Scale bars 20 μm (A).
Additional file 10: Phosphorylated p130Cas expression correlates
with CrkI/II expression in human breast cancer tumors.
Immunofluoresence of CrkI/II and phosphorylated p130Cas was
performed on frozen human basal breast cancer tissue. CrkI/II mRNA
expression from these patients was also assessed by microarray analysis.
TN = triple negative, ER = estrogen receptor. Scale bars 20 μm (A).
Abbreviations
Cas: Crk-associated substrate; Cdc42: cell division cycle 42; Crk: CT10
regulator of kinase; Crk-L: Crk-Like; Dock180: dedicator of cytokinesis 1; ER:
estrogen receptor; FBS: fetal bovine serum; GTP: guanosine triphosphate; H &
E: hematoxylin and eosin; HER2: human epidermal growth factor receptor 2;
LMP: MSCV-LTR-mir30-PIG; mRNA: messenger ribonucleic acid; MUHC: McGill
University Health Centre; PI3K: phosphoinositide 3-kinase; PR: progesterone
receptor; Rac1: ras-related C3 botulinum toxin substrate 1; RLU: relative
luciferase units; RNAi: RNA interference; SDS-PAGE: sodium dodecyl sulfate
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